沙利度胺联合CAG方案治疗老年急性髓系白血病的效果及安全性

Clinical effect and medication safety of thalidomide combined with CAG regiment in the treatment of elderly acute myeloid leukemia

目的探讨应用沙利度胺联合CAG方案治疗老年急性髓系白血病(AML)的短期疗效、可行性及安全性。方法随机抽取我院收治的72例AML患者作为研究对象,按照治疗方案将其分为两组,每组36例。在CAG方案化疗治疗基础上,观察组加用沙利度胺治疗,对照组加用地西他滨治疗。对比两组的治疗效果、预后及不良反应情况。结果两组的治疗总有效率、随访0~3年的复发率及随访0~1年内的生存率比较,差异无统计学意义(P>0.05),而观察组随访2~3年的生存率及随访期的不良反应总发生率显著优于对照组(P<0.05)。结论对于老年AML患者,沙利度胺服用方便、毒副作用小,有助于提高CAG方案的短期疗效及患者生存率,值得在难治性、老年性白血病临床治疗进一步推广。

Objective To discuss the short -term efficacy, feasibility and safety of thalidomide combined with CAGregiment in the treatment of elderly acute myeloid leukemia （AML）. Methods A total of 72 cases of patients with AMLtreated in our hospital were randomly selected as the research objects and divided into two groups according to thetreatment methods, with 36 cases in each group. On the basis of CAG regiment, the observation group added thalidomide,while the control group added decitabine. The therapeutic effects, prognosis and adverse reactions were compared betweenthe two groups. Results There were no significant differences between the two groups in the total effective rate, the follow-up 0-3 year recurrence rate and the follow-up 0-1 year survival rate between the two groups（P〉0.05）. However, thefollow-up 2-3 year survival rate and total incidence of adverse reaction in the follow-up period in the observation group weresignificantly better than those in the control group（P〈0.05）. Conclusion For elderly patients with AML, thalidomide is easyto take and has less toxic and side effects. It is helpful to improve the short-term efficacy and survival rate of patients withCAG, it＇s worthy of further promotion in the clinical treatment of refractory and senile leukemia.